Clinical trials: Breast Cancer/ Metastatic Breast Cancer
Breast Cancer
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Taxanes (such as paclitaxel) are highly active to treat breast cancer. Abraxane® (nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and tolerability.
- Trial name
- ABC (NCT00479674)
- Testing
- Abraxane, Bevacizumab, Carboplatin
- Where
- 4 sites in United States
- Volunteers
- 41 people
- Sponsor
- Duke University
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Secondary Lymphedema, Breast Cancer
Supermicrosurgery for Breast Cancer Survivors With Lymphedema.
A randomised prospective investigation of volume and quality of life results with lymphovenous anastomosis in patients with unilateral arm lymphedema after breast cancer using Indocyanine Green lymphangiography and MD Anderson…
- Trial name
- NCT03578380
- Testing
- Surgery, Compression and drainage therapy
- Where
- Norway
- Volunteers
- 100 people
- Sponsor
- Sykehuset Telemark
Triple Negative Breast Cancer
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
The DIAMOND study is being carried out to evaluate if Datopotamab deruxtecan (Dato-DX) in combination with Durvalumab is more effective than Dato-DXd alone in treating PDL1-negative advanced or metastatic triple negative breast…
- Trial name
- DIAMOND (NCT06954480)
- Testing
- Datopotamab Deruxtecan (Dato-DXd), Durvalumab
- Where
- 2 sites in United Kingdom
- Volunteers
- 140 people
- Sponsor
- Queen Mary University of London
Breast Cancer
Whole-body MR in Staging Bone and Soft Tissue Metastases in Breast Cancer Patients(MetaMaRBo)
Prospective MR-imaging study : role of magnetic resonance (MR) and Diffusion weighted imaging (DWI) MR in staging and therapy assessment in breast cancer patients with bone metastases.
- Trial name
- METAMARBO (NCT01291082)
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Breast Cancer
Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis
Basis: Brain metastasis is very common in breast cancer, and HER2 positivity is a risk factor for high incidence of brain metastasis, with approximately 50% of HER2+ MBC cases experiencing brain metastasis.
- Trial name
- NCT06015113
- Testing
- Disitamab Vedotin plus pyrotinib or naratinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xi'an International Medical Center Hospital
Breast Cancer
Study of E7389 for Advanced or Metastatic Breast Cancer
The purpose of this study (E7389-J081-224; hereafter referred to as Study 224) is to evaluate the safety of patients who continue to receive E7389 after completing the Phase II clinical study (E7389-J081-221; hereafter referred…
- Trial name
- NCT00965523
- Testing
- Eribulin Mesylate
- Where
- 5 sites in Japan
- Volunteers
- 81 people
- Sponsor
- Eisai Co., Ltd.
Breast Cancer
The Rechallenge of ADCs in MBC Patients
To investigate the efficacy and safety of ADC rechallenge
- Trial name
- NCT05571618
- Testing
- ADC
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
ER-Positive Breast Cancer, HER2-negative Breast Cancer
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
The study will investigate if CDK4/6 inhibitor holiday will reset the cell cycle process to respond to the combination of fulvestrant and abemaciclib, and this approach may represent an effective therapeutic strategy to manage…
- Trial name
- NCT05305924
- Testing
- Fulvestrant Run-In
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The Methodist Hospital Research Institute
Breast Cancer, Ovarian Cancer
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat metastatic breast, ovarian, endometrial or cervical cancer not responding to standard treatment.
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- NCT00319748
- Testing
- 852A
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Metastatic Breast Cancer
Androgen Therapy for Management of Estrogen/Progesterone Receptor Negative ER(-)PR(-) Metastatic Breast Cancer
This study is for patients with breast cancer that has spread to other tissues and organs. The purpose of this study is to identify patients who may respond favorably to certain types of hormonal therapy.
- Trial name
- NCT00303615
- Testing
- Fluoxymesterone 10 mg, Anastrozole 1 mg
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Legacy Health System
Metastatic Breast Cancer
Genetic Characteristics of Metastatic Breast Cancer Patients
Genomic analysis for metastatic breast cancer(MBC) patients Participant (Inclusion criteria) 1. Patients who diagnosed metastatic/stage IV breast cancer 2.
- Trial name
- NCT04258735
- Testing
- Genomic analysis
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Samsung Medical Center
Primary Operable Breast Cancer
Perioperative Administration of COX 2 Inhibitors and Beta Blockers to Women Undergoing Breast Cancer Surgery
Surgery for breast cancer has a major role in enhancing long term survival and cure, but several physiological aspects associated with surgery are implicated as enhancing tumor spread and formation of distant metastases.
- Trial name
- NCT00502684
- Testing
- Propranolol, etodolac
- Where
- 3 sites in Israel
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Kaplan Medical Center
Breast Cancer Metastatic
Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer
▪ Fulvestrant With Ribociclib versus Physician's choice treatments for the patients who recurred after completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer as first line treatment
- Trial name
- NCT06849947
- Testing
- Ribociclib with fulvestrant, Physician's choice treatments group
- Volunteers
- 272 people
- Sponsor
- Yeon Hee Park
Metastatic Breast Cancer
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients
Despite the clear benefit of a combination therapy of pertuzumab plus trastuzumab plus docetaxel when compared with a combination therapy of trastuzumab and docetaxel the study populations of the CLEOPATRA trial might be slightly…
- Trial name
- PerFECT (NCT02642458)
- Where
- 37 sites in Germany
- Volunteers
- 300 people
- Sponsor
- University Hospital Tuebingen
Virtual Staining, Lymph Node Metastasis
Evaluation of Axillary Lymph Node Metastasis Status of Breast Cancer Based on Pathological Images and Virtual Staining
The goal of this observational study is to develop an artificial intelligence model to transform unstained lymph node tissue slice images directly into stained images.
- Conditions
- Virtual Staining, Lymph Node Metastasis, Breast Cancer, Digital Pathology
- Trial name
- NCT06486155
- Volunteers
- 2,200 people
- Sponsor
- Yunnan Cancer Hospital
Lymphadenectomy, Breast Cancer
Early Detection of Lymphedema After Cancer Treatments
Many clinical situations in oncologic surgery imply the need to dissect more or less extensively lymph node stations which are in direct relation with the lymphatic drainage of the anatomical region affected by cancer.
- Trial name
- NCT02415725
- Testing
- Indocyanine Green
- Where
- Belgium
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Breast Cancer
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-M02D1 in patients with locally advanced or metastatic triple negative breast cancer or other solid tumors will be investigated to determine the dose-limiting toxicity (DLT)…
- Trial name
- NCT05339685
- Testing
- BL-M02D1
- Where
- 10 sites in China
- Volunteers
- 82 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Breast Cancer
Treatment With Pyrotinib-Based Therapy in Lapatinib Resistant HER2-Positive Metastatic Breast Cancer
This is a multicenter, observational, single-arm real world study to evaluate the efficacy and safety of pyrotinib after lapatinib progression.
- Trial name
- NCT04899128
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer
Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00009763
- Testing
- filgrastim, monoclonal antibody m170, cyclosporine
- Where
- United States
- Sponsor
- University of California, Davis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.